We have tested in healthy mice to get an insight, but detailed biodistribution should be done with relevant models and with encapsulated drugs / molecules as this affects the biodistribution. We have tried s.c. (subcutaneous) administration using one or more imaging modalities as we have optimized labeling (PET, SPECT and fluorescent tracking), i.v. (tail vein injection and retroorbital), i.a. (intra-articular), and i.p. (intraperitoneal).